Centre Hospitalier D Avignon
- Address
- lock Available on a paid plan
Centre Hospitalier D'Avignon - Comprehensive Clinical Research Center
Centre Hospitalier D'Avignon is a leading French medical research institution conducting diverse clinical trials across multiple therapeutic domains. The center demonstrates particular expertise in hematologic malignancies and oncology research, with extensive experience in both solid tumors and blood cancers.
- Hematologic Oncology: Multiple myeloma, acute lymphoblastic leukemia, lymphomas (diffuse large B-cell, follicular, peripheral T-cell), myelodysplastic syndromes, and myeloproliferative neoplasms
- Thoracic Oncology: Non-small cell lung cancer with immunotherapy and targeted therapies including checkpoint inhibitors and EGFR-targeted treatments
- Autoimmune and Inflammatory Conditions: Uveitis, Behçet's disease, ANCA vasculitis, immune thrombocytopenia, and Crohn's disease
- Critical Care Medicine: Septic shock management, cardiogenic shock, diabetic ketoacidosis, and dialysis-related complications
The center actively participates in phase II and III trials evaluating novel immunotherapeutic agents, including bispecific antibodies (epcoritamab, odronextamab, teclistamab), checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab), and targeted therapies. Research at Centre Hospitalier D'Avignon emphasizes personalized medicine approaches, with studies incorporating minimal residual disease monitoring, therapeutic drug monitoring, and biomarker-driven treatment strategies. The institution's portfolio includes trials for rare conditions such as cryoglobulinemia and ampullary adenocarcinoma, alongside comprehensive investigations in renal disease, hepatocellular carcinoma, and advanced prostate cancer.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 16 therapeutic areas and 15 of 181 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 147 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 26 by active trials.
lock +25 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +19 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier D Avignon
lock Showing 1 of 103 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy | Merck Sharp & Dohme LLC | Phase II | Not Recruiting | Apr 2021 | Oct 2024 |
IMP list
lock Showing 1 of 181 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Lenalidomide | 11 | Unknown | 2019-10-07 | 2025-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.